Curriculum vitae et studiorum

PERSONAL INFORMATION

Family name: **Peyvandi**
First name: **Flora**
Date of birth: -omissis-
Nationality: Italian

Researcher unique identifier(s): orcid.org/0000-0001-7423-9864,
Scopus Author ID: 7004174530
URL for web site: http://www.florapeyvandi.eu
Email: flora.peyvandi@policlinico.mi.it or flora.peyvandi@unimi.it

EDUCATION

Jan 2001	Research Doctorate, University of Milan, Milan – Italy "Phenotype and genotype characterization of rare bleeding disorders"
Nov 2000	PhD, University of Maastricht, Maastricht - The Netherlands "Rare bleeding disorders"
Nov 1996	Specialization in Haematology, University of Milan, Milan – Italy
1991	Doctor of Medicine, Medical school of University of Milan, Milan - Italy

CURRENT POSITION(S)

2022 - 2025	Director, Department of Pathophysiology and Transplantation, University of Milan, Milan – Italy
2022 – present	Director, Department of Rare Diseases
2017 - present	Director of the Unit of Internal Medicine - Haemostasis and Thrombosis, IRCCS Maggiore Hospital, Milan – Italy
2016 – present	Full Professor of Internal Medicine, Department of Pathophysiology and Transplantation, University of Milan, Milan – Italy
2010 – present	Director of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan – Italy

INSTITUTIONAL RESPONSIBILITIES

2022 – present	University of Milan, Milan-Italy: Member of the Board of Directors of the Medical School
2019 – present	IRCCS Maggiore Hospital, Milan – Italy: Responsible for the Rare Diseases Center
2017 – present	IRCCS Maggiore Hospital, Milan – Italy: Member of the Board of Directors, Vice-Director of the Internal Medicine Department and Member of the Scientific and Technical Committee
2017 – present	University of Milan, Milan – Italy: Member of the "Osservatorio della Ricerca" (research committee)

PREVIOUS POSITIONS

IRCCS Maggiore Hospital, Milan – Italy:

2021 - 2022	Scientific Director ad interim, IRCCS Maggiore Hospital, Milan – Italy
2010 - 2017	Director of the Internal Medicine - Hemostasis and Thrombosis Unit 2001 – 2010 Associate Medical Director, Internal Medicine Department

University of Milan, Milan – Italy:

2020 - 2022	Director, Postgraduate Internal Medicine School,
2017-2022	Vice-Director, Department of Pathophysiology and Transplantation
2005-2016	Associate Professor of Internal Medicine

Other institutions:

2011 - 2016	Visiting Professor, University College of London, Cancer Institute, London – UK.
2009 - 2011	Professorial Research Associate, University College of London, Cancer Institute (UCL), London – UK

FELLOWSHIPS AND AWARDS

Fellowship

1998 - 2000	Research fellow, Beth Israel Deaconess Medical Centre, VA Harvard Medical School, Boston - USA
1997- 1998	Research fellow, Katharine Dormandy Haemophilia Centre & Haemostasis Unit, Royal Free Hospital, University College London (UCL), London – UK

Awards

2021	Recti Eques Award – Paladini Italiani della Salute
2016	Hilfenhaus Award for outstanding contribution to the provision of safe and efficacious Plasma Protein Therapies. Plasma Protein Therapeutics Association (PPTA)
2015	Research and Innovation Award, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2014	"Grande Ippocrate" award for Scientific Research and Dissemination.
1998	Young Investigator Award for best scientific communication, 17th Congress of the International Society on Thrombosis and Haemostasis. Washington DC - USA

TEACHING ACTIVITIES

Since 2005, I have been teaching on the diagnosis, cellular and molecular therapy of microangiopathies and bleeding disorders at School of Medicine, Post-graduate Schools in Internal Medicine and of Hematology, IRCCS Maggiore Hospital – University of Milan, Italy and at First degree course in Medical Biotechnologies and Molecular Medicine, University of Milan, Italy. I am also member of the teaching staff and of the managing council Post-graduate school in Translational Medicine. Since 2008 I have given lectures in the frame of the Educational courses of the International Society on Thrombosis and Haemostasis (ISTH) and the World Federation of Hemophilia (WFH).

SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS

Since 2001, I have been tutoring and coordinating scientific activities of graduation students (9), medical specialist training (5) and of PhD and Master students (16) at the University of Milan, Italy. I also co-supervise PhD projects based at the University of Leiden, The Netherlands (3), at the University of Maastricht, The Netherlands (1), and at University College London, UK (1).

MENTORING: Major contributions to the early careers of excellent researchers

Among others, she supervised and mentored the PhD programme of three excellent researchers:

- **Luca Andrea Lotta**, for research on the pathophysiology of thrombotic thrombocytopenic purpura. Since 2013, Dr Lotta has been working at the MRC – Epidemiology Unit, University of Cambridge, UK in order to take on the discovery of biomarkers and causal mechanisms for the metabolic consequences of obesity in the frame of the EU-funded EMIF-Metabolic project, for which he serves in the Executive Committee. He recently published as leading author in Nature Genetics, PLoS Medicine and JAMA.
- **Khaled M.S. Musallam**, for studies on beta-thalassemia. After that, Dr Musallam founded EVIDA Medical, a clinical consulting agency which uses in-house expertise and an established network of advisers to provide guidance on the generation and utilization of evidence in clinical research and healthcare education. He is also President of the International Network of Hematology, a non-profit scientific organization dedicated to the optimization of knowledge, clinical care and education on hematologic disorders through a network of opinion leaders. He is also continuing his research on thalassemia as witnessed by the numerous scientific publications.
- **Ali T. Taher**, for studies on morbidities of hemoglobinopathies. Dr Taher is now Professor of Medicine at the Division of Hematology & Oncology, Department of Internal Medicine, at the American University of Beirut Medical Center, Beirut, Lebanon. He is also an adjunct Professor of Hematology & Medical Oncology at Emory School of Medicine, Atlanta, GA, USA.

COMMISSIONS OF TRUST

2022-present	President of the Executive Committee of the Board of the University professors in Internal Medicine (COLMED/09)
2019 – 2022	Member of the Executive Committee of the Board of the University professors in Internal Medicine (COLMED/09)

2016 – present Board Member for the evaluation of the National Scientific Qualification, Italian Ministry of Education, University and Research (MIUR)
2016 – present Associated editor of the Journal of Thrombosis and Haemostasis (JTH)
2011 – present Section Editor of the Orphanet Journal of Rare Diseases (OJRD)

Scientific societies/academy and patients associations:

International Society of Thrombosis and Haemostasis (ISTH)

2022 – 2024 President
2018 – present Member of the Executive Committee
2020 – 2022 President-Elect
2020 – 2022 Member of the Scientific Program Committee Task Force
2018 – 2022 Chairman of the Education and Outreach Committee
2016 – 2022 Member of the Guidelines and Guidance Committee
2016 – 2020 Elected member of the ISTH Council
2010 – 2014 Chair of the of the Scientific and Standardization Committee on Factor VIII, Factor IX & Rare Coagulation Disorders

World Federation of Hemophilia (WFH)

2022 – present Member of the Gene Therapy Registry Steering Committee
2016 – present Member of the Coagulation Product Safety, Supply and Access (CPSSA) Committee
2018 – 2022 Member of the VWD & Rare Bleeding Disorders Committee
2018 – 2022 EHC Liaison Medical Advisory Board
2016 – 2018 Chair of the Education Advisory Committee and member of the Humanitarian Aid Committee
2014 – 2018 Member of the Board of Directors and of the Medical Advisory Board
2012 – 2018 Chair of the VWD & Rare Bleeding Disorders Committee
2012 –2015 Member of the International Hemophilia Training Centre (IHTC) Committee

European Association for Haemophilia and Allied Disorders (EAHAD)

2022 – 2024 Past-President of the Executive Committee
2020 – 2022 President of the Executive Committee
2018 – 2020 Vice-President of the Executive Committee
2015 – present Member of the Executive Committee

European Haemophilia Consortium (EHC)

2019 – 2020 Chairperson of the Medical Advisory Group
2012 - 2018 Member of the Medical Advisory Group

EMA/Advisory Committee Experience

- 07/06/2019: European Symposium Optimal Treatment of Haemophilia, Wildbad Kreuth Initiative V (EDQM, EP, PEI, University Munich)
- 08/06/2018: EMA Haemophilia Registries Workshop
- 08/02/2017: Presentation on Factor VIII Art.31 referral to PRAC
- 28/11/2016: Ad hoc expert group (SAG) for the treatment of haemophilia A and haemophilia B
- 02/07/2015: EMA Haemophilia Registries Workshop
- 29/11/2013: EMA-EDQM workshop on potency assays
- Nov 2013: inclusion in the EMA experts database team

Others

2018 – present Italian Ministry of Health: Member of the Technical Health Committee – Health Research Section
2015 - present Member of the Board of the Foundation for the European Congress on Thrombosis and Haemostasis
2015 –2017 Member of the Awards Committee of the American Society of Hematology (ASH)

Academy membership

Dr Peyvandi is member of many Italian, European and international scientific societies and patients' organisations (Associazione Italiana Centri Emofilia -AICE, Società Italiana per lo Studio dell'Emostasi e della Trombosi -SISET, Società Italiana di Medicina Interna -SIMI, European Association for

Haemophilia and Allied Disorders -EAHAD, International Society on Thrombosis and Haemostasis - ISTH, American Society of Hematology -ASH)

MAJOR RESEARCH FIELDS:

- Clinical and laboratory aspects of hereditary coagulation disorders (thrombophilia and haemophilia)
- Genotype and phenotype characterisation of patients affected with rare coagulation disorders and von Willebrand disease
- Biochemical characterisation of mutant recombinant proteins causing rare coagulation disorders and von Willebrand disease
- Implementation of a International on-line database for the collection of clinical, laboratory and therapeutic data related to patients affected by rare bleeding disorders (RBDs: fibrinogen deficiency, Factor (F) II, FV, FVII, FV+FVIII, FX, FXI and FXIII) (www.rbdd.org)
- Development of new techniques for prenatal diagnosis in early stage of pregnancy in women carriers of haemophilia or affected by one of the other rare coagulation disorders
- Gene mutation, transcription, translation and transport analysis of FVIII in haemophilic patients with inhibitors
- Implementation of a novel thrombotic thrombocytopenic purpura database for the collection of clinical, genetic and therapeutic data (www.ttpdatabase.org)
- Basis research on molecular and immunological aspects of patients affected by autoimmune thrombotic thrombocytopenic purpura.
- Next-generation DNA sequencing to study the genetic predisposition to thrombotic and haemorrhagic disorders (myocardial infarction, deep vein thrombosis and haemophilia)

MAJOR COLLABORATIONS

- Belgium: K. Vanhoorelbeke, Laboratory for Thrombosis Research, KU Leuven, Kortrijk
- France: S. Lacroix-Desmazes, Centre de Recherche des Cordeliers, Paris
- Italy: S. Duga and R.Asselta, Medical genetics and RNA biology Unit, Humanitas University, Milan; R. De Cristofaro, Hemostasis and Thrombosis Unit, Gemelli Hospital, Rome
- The Netherlands: F.R. Rosendaal, Dpt of Clinical Epidemiology, Leiden University Medical Center
- Switzerland: P. De Moerloose, Division of Angiology and Haemostasis, University Hospitals of Geneva
- UK: M. Makris, Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield; M. Scully, Dpt of Haematology and Haemostasis Research Unit, University College London Hospital,
- USA: K. Bauer, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; R. Gibbs, Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX; S. Kathiresan, Center for Human Genetic Research and Cardiovascular Research Center, Harvard Medical School, Boston, CA; A.D. Shapiro, Indiana Hemophilia and Thrombosis Center, Indianapolis, IN

Publications

Total number of publications in peer-reviewed, international journals	669
Total number of citations (1996-2023)	28968
Total Number of citations (2013-2023)	15034
H-index (scopus)	77
N of first author	97
N of last author	250
N of single author	8

Source: https://www.scopus.com/freelookup/form/author.uri (updated: September 1st 2023)

Ten representative publications, from the last ten years, as main author

As first author

1. **Peyvandi F,** et al. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016;374:2054-64. **(IF: 72.4; N° citations: 125)**
2. **Peyvandi F**, et al. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388:187-97. **(IF: 47.8; N° citations: 68)**
3. **Peyvandi F**, et al. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 2016;374:511-22 **(IF: 72.4; N° citations: 85)**
4. **Peyvandi F**, et al Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost. 2012;10:1938-43. **(IF: 6.1; N° citations: 57)**
5. **Peyvandi F**, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012;10:615-621. **(IF: 6.1; N° citations: 138)**
6. **Peyvandi F**, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica. 2008;93:232-9. **(IF: 6.0; N° citations: 146)**

As last author

7. Gorski MM, et al**.** Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients. Blood. 2016;127:2924-33. **(IF: 13.2; N° citations: 10)**
8. Lotta LA, et al. Next-generation sequencing study finds an excess of rare, coding single nucleotide variants of ADAMTS13 in patients with deep vein thrombosis. J Thromb Haemost. 2013;11:1228-39. **(IF: 5.6; N° citations: 27)**
9. Lotta LA, et al. Residual plasmatic activity of ADAMTS13 correlates with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood. 2012;120:440-8. **(IF: 9.1; N° citations: 64)**
10. Lotta LA, et al. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat. 2010;31:11-9. **(IF: 6.0; N° citations: 102)**

Granted projects

2022: Anti-PEG antibodies and their pathophysiological role in the personalised management of patients with hemophilia. Bando Ricerca Finalizzata, Italian Ministry of Health, Rome, Italy (Principal Investigator, 36 months)

2022: Innovative approaches to identify causative genetic variants in patients with unexplained bleeding disorders. Bando PNRR 2022. Italian Ministry of Health, Rome, Italy (Principal Investigator, 24 months)

2019: Early Stage Researchers EDUCational Program on Factor VIII Immunogenicity. MSCA-ITN-(ETN) H2020-MSCA-ITN-2019 (Beneficiary, 48 months)

2018: Identification of novel genetic risk factors located in the conserved haplotype region surrounding the LCT locus on chromosome 2q21. Ricerca Finalizzata, Italian Ministry of Health, Rome, Italy (Principal Investigator, 36 months)

2018: Inhibitor development in previously untreated patients with severe hemophilia A, first treated with plasma-derived factor VIII and then switched to recombinant product: an international, multicenter, prospective, controlled, randomized, open label, clinical trial, SIPPET 2. Agenzia Italiana del Farmaco, bando Ricerca Indipendente, Rome, Italy (Principal Investigator, 36 months)

2017: RBDD-PLG project; international retrospective and prospective study of individuals affected with hypoplasminogenemia. Indiana Hemophilia & Thrombosis Center, indianapolis, IN, USA (Co-Principal Investigator, 36 months)
2017: High throughput analysis of antibody binding prophiles in previously severe haemophilia A. Grifols Investigator Sponsored Research (Principal Investigator, 24 months)
2016: Hemophilia Treatment Centre Twinning Programme between the Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan – Italy and Comprehensive Care Centers in Iran: Pediatric Congenital Bleeding Disorder Research Center, Mofid Children's Hospital, Tehran, Iran. World Federation of Hemophilia (WFH) (Principal Investigator, 36 months)
2013: Diagnosi prenatale: l'uso delle cellule fetali per la diagnosi genetica non invasiva in donne portatrici di emofilia. Italo Monzino Foundation, Milan – Italy (Principal Investigator, 36 months)
2013: Microangiopatie trombotiche. Italo Monzino Foundation, Milan – Italy (Principal Investigator, 36 months)
2013: Influence of aggregation extent of FVIII in pharmaceutical concentrates on their biochemical properties and coagulant efficacy. Funded by Biotest AG (Principal Investigator, 24 months)
2012: Costituzione di una rete lombarda per lo studio e il trattamento dei pazienti sottoposti a procedure di aferesi terapeutica. Regione Lombardia, Direzione generale Sanità - Italy (Partner, 24 months)
2012: Hemophilia Treatment Centre Twinning Programme between the Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan – Italy and Esfahan Hemophilia center, Sayedalshohada Hospital, Esfahan – Iran. World Federation of Hemophilia (WFH) (Principal Investigator, 36 months)
2012: European Haemophilia Network (EUHANET). Commission of the European Union, The Executive Agency for Health and Consumers (EAHC) (Workpackage leader, 36 months)
2012: Prospective evaluation of the intensity of bleeding episodes in patients with coagulation factor XIII deficiency (PRO-RBDD). Funded by NovoNordisk, Denmark (Principal Investigator, 72 months)
2011: New risks factor for complex atherothrombotic diseases – role of von Willebrand factor and of the metalloprotease ADAMTS13. Fiera Foundation, Milan - Italy (Principal Investigator, 17 months out of 72)
2011: Discovery of genetic determinants of inhibitor development in hemophilia a by exome sequencing. Bayer Hemophilia Awards Program - Special project award (Principal Investigator, 24 months)
2011: Biochemical, conformational and functional characterization of a novel purified FVIII concentrate from BioTest: a comparative study. Funded by Biotest AG (Principal Investigator, 24 months)
2011: Multiplexed next-generation sequencing of the haemostatic exome in deep vein thrombosis. Cariplo Foundation, Milan - Italy (Principal Investigator, 21 months)
2010: Modello di integrazione tra attivita' di ricerca sperimentale e pratica clinica: l'approccio alle microangiopatie trombotiche. Regione Lombardia, Direzione generale Sanità - Italy (Partner, 24 months)
2010: Microangiopatie trombotiche. Italo Monzino Foundation, Milan – Italy (Collaborator, 36 months)
2010: Enlargement of the European network of the Rare Bleeding Disorders (EN-RBD). European Association of Hemophilia and Allied Disorders (EAHAD), Sheffield – UK (Principal Investigator, 12 months)
2010: Programma di lavoro del Presidio di coordinamento regionale per le coagulopatie congenite. Regione Lombardia, Direzione generale Sanità - Italy (Principal Investigator, 36 months)
2009: Inhibitor development in previously untreated patients (PUPs) or minimally blood component-treated patients (MBCTPS) when exposed to von Willebrand factor-containing factor VIII concentrates and to recombinant factor VIII concentrates: an international, multicentre, prospective, controlled, randomised, open label, clinical trial. Angelo Bianchi Bonomi Foundation, Milan – Italy (Partner, 72 months)
2009: Cellule fetali nel sangue materno. Una promettente tecnica non invasiva di diagnosi prenatale delle malattie genetiche. Paracelso Foundation, Milan – Italy (Principal Investigator, 12 months)
2009: Determinazione del sesso fetale nel I° trimestre di gravidanza mediante tecniche non invasive. Italo Monzino Foundation, Milan – Italy (Principal Investigator, 36 months)
2008: Determinazione del sesso fetale nel I0 trimestre di gravidanza mediante tecniche non invasive. PUR (ex FIRST) grant, University of Milan, Milan – Italy (Principal Investigator, 12 months)
2008: Menorrhagia and other gynecological problems in women affected by rare bleeding disorders. Laboratoire français du Fractionnement et des Biotechnologies (LFB) – France (Principal Investigator, 12 months)
2007: Establishment of a European Network of Rare Bleeding Disorders. Istituto Superiore di Sanità,

Rome – Italy (Principal Investigator, 24 months)
2007: Meccanismi molecolari patogenetici nella carenza combinata dei fattori della coagulazione V e VIII (F5F8D). FIRST grant, University of Milan- Italy (Principal Investigator, 12 months)
2007: Biochemical and molecular characterization of the interaction between Von Willebrand Factor and ADAMTS-13: new hypotheses on physiopathogenesis of thrombotic microangiopathic diseases. PRIN grant, Italian Ministry of University and Research – Italy (Principal Investigator, 24 months)
2007: Establishment of an European Network of Rare Bleeding Disorders. Commission of the European Unit - Public Health Executive Agency (PHEA) (Principal Investigator, 36 months)
2007: Rare bleeding disorders: development of a European Registry and characterization of the molecular mechanisms. Telethon – Italy (Collaborator, 36 months)
2007: Thrombospondin-1 (TSP-1), ADAMTS13 and von Willebrand (VWF): role in the thrombotic thrombocytopenic purpura (TTP). Funded by Baxter – Italy (Principal Investigator, 12 months)
2006: Trombospondina-1 (TSP-1), ADAMTS13 e fattore di von Willebrand (VWF): ruolo nella porpora trombotica trombocitopenica (TTP). FIRST grant, University of Milan- Italy (Principal Investigator, 12 months)
2006: Markers genetici nella prevenzione farmacologica dell'ictus ischemico giovanile. Ricerca Finalizzata Ministry of Health – Italy (Collaborator, 24 months)
2006: Hemophilia Treatment Centre Twinning Programme between the Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan – Italy and Hemostasis & Thrombosis unit, Hematology research center, Dastgheyb Hospital, Shiraz medical University of Science, Shiraz - Iran, World Federation of Hemophilia (WFH) (Principal Investigator, 36 months)
2006: Mantenimento ed implementazione di un Database Internazionale sulle malattie rare della coagulazione. Banca Fideuram (Principal Investigator, una tantum)
2005: Registro Internazionale sui pazienti affetti da Porpora Trombotica Trombocitopenica (TTP): caratterizzazione fenotipica e genotipica. FIRST grant, University of Milan- Italy (Principal Investigator, 12 months)
2005: Determinazione del sesso fetale nel I° trimestre di gravidanza mediante tecniche non invasive. Italo Monzino Foundation, Milan – Italy (Principal Investigator, 36 months)
2005: Molecular genetics of hereditary rare bleeding disorders in Indian population. Ministry of Foreign Affairs, General Directorate for Cultural Promotion and Co-operation – Italy (Principal Investigator, 24 months)
2004: Association between polymorphisms in gene encoding for inflammation protein and juvenile myocardial infarction. COFIN grant, Italian Ministry of University and Research - Italy (Collaborator, 24 months)
2004: Sviluppo di nuovi test diagnostici quantitativi e funzionali della proteasi del fattore von Willebrand per la diagnosi delle malattie trombotiche microangiopatiche. IRCCS Maggiore Hospital, Milan - Italy (Principal Investigator, 12 months)
2003: Valutazione di polimorfismi genetici associati alla trombosi e farmacogenomica degli anticoagulanti con nuove tecnologie ad alta resa. IRCCS Maggiore Hospital, Milan – Italy (Principal Investigator, 12 months)
2003: Inflammation genes and development of myocardial infarction at a young age. Retrospective case-control study of 2000 cases and 2000 controls enrolled by 125 Italian Coronary Care Unit in eight years. Cariplo Foundation, Milan - Italy (Principal Investigator, 12 months)
2003: Phenotype and genotype characterization of recessively inherited coagulation disorders. Bayer Hemophilia Awards Program - Early career investigator award. (Principal Investigator, 24 months)
2003: Rare inherited coagulation disorders: clinical and molecular characterization to develop a National Registry and molecular tests for prenatal diagnosis. Telethon – Italy (Collaborator, 36 months)
2003: Clinical and molecular diagnosis of rare coagulation disorders. UniCredit Private Bank (Principal Investigator, una tantum)
2003: Membrane metalloproteinases involved in disorders of haemostasis. COFIN grant, Italian Ministry of University and Research – Italy (Collaborator, 24 months)
2002: Quantitative and functional assays of the VWF-cleaving protease (ADAMTS-13) for thrombotic thrombocytopenic purpura. Cariplo Foundation, Milan – Italy (Principal Investigator, 12 months)
2002: Rare inherited coagulation disorders: clinical and molecular characterization to develop a National Registry and molecular tests for prenatal diagnosis. COFIN grant, Italian Ministry of University and

Research – Italy (Collaborator, 24 months)
2002: Hemophilia Treatment Centre Twinning Programme between the Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan – Italy and Nemazee Hospital, Shiraz – Iran. World Federation of Hemophilia (WFH) (Principal Investigator, 48 months)
2001: In vivo and in vitro studies of angiogenetic process by VEGF in patients by myocardial infarction. Cariplo Foundation, Milan - Italy (Principal Investigator, 12 months)
2001: Difetti autosomici recessivi della coagulazione del sangue: causa di carenza di fattori della coagulazione. Italo Monzino Foundation, Milan – Italy (Principal Investigator, 24 months)
2000: Hemophilia Treatment Centre Twinning Programme between the Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan – Italy and the Teheran Iman Khomeini Hospital Hemophilia Center, Tehran – Iran, awarded by World Federation of Hemophilia (WFH) (Principal Investigator, 36 months)
2000: Diagnosi prenatale e precoce delle malattie ereditarie. Ricerca Finalizzata Ministry of Health – Italy (Principal Investigator, 12 months)
1998: Caratterizzazione molecolare della carenza della carenza di fattore X della coagulazione. Bando giovani ricercatori, University of Milan – Italy (Principal Investigator, 24 months)

Invited presentations to peer-reviewed, internationally established conferences and/or international advanced schools
In the last ten years, Dr Peyvandi has been invited as an expert speaker at over 100 national and international congresses on internal medicine, haematology or thrombosis and haemostasis. In these occasions, she shared her experience in understanding causes and mechanisms of haemostatic disorders, harmonising laboratory methods as well as evaluating the effectiveness and safety of therapeutic products. Many of these presentations were focussed on rare bleeding disorders, and in particular on their systematic categorisation in terms of clinical severity and symptoms. Recently, the results of the SIPPET trial have generated major interest from patient organisations, physicians and regulatory agencies, as witnessed by the lively debates at various meetings (WFH, ISTH, EAHAD).

Research expeditions
Since many years, Dr Peyvandi has been collaborating with Fondazione Paracelso, Milan – Italy to help implement expertise regarding methods and techniques in haemophilia centres in disadvantaged countries such as Afghanistan and Zambia, which she visited in 2011 and in 2014, respectively.

Organisation of international conferences
2023: Chair of the 12th BIC Conference 2023 Organising and Scientific Committee, Palermo, Italy
2021: Chair of the 11th BIC Conference 2021 Organising and Scientific Committee, Venice, Italy
2019: Chair of the Joint BIC & INHIBITORS International Conference 2019 Organising and Scientific Committee, Genoa, Italy
2018: Co-President of the 2020 ISTH congress, Milan, Italy
2018: Chair of the 2nd International Conference on Inhibitors in Coagulation disorders (Inhibitors2018) (Milan, Italy)
2018: Board of the 2018 European Congress on Thrombosis and Haemostasis (Marseille, France)
2017: Co-chair of the 9th BIC International Conference Organising Committee (Rome, Italy)
2017: Member of the Hemorrhagic Disorders, Hemophilia Scientific Topic Program Subcommittee for the XXVI ISTH Congress
2016: Board of the 2016 European Congress of Thrombosis and Haemostasis (The Hague, The Netherlands)
2016: Chair of the International Conference on Inhibitors in Hemophilia A (Milan, Italy)
2014: Co-chair of the 8th BIC International Conference Organising Committee (Bari, Italy)
2013: Member of the International Advisory Board for the XXIV ISTH congress
2007: Member of the Scientific Program Committee of European Hematology Association (EHA)
2007, 2008 and 2010: Organiser of the three workshops of the Establishment of a European Network of Rare Bleeding Disorders (EN-RBD) working group, in the framework of the Public Health Programme, held in Milan, Italy; Copenhagen, Denmark and Athens, Greece

Leadership in industrial innovation or design

- Close collaboration and consulting activities with Kedrion Biopharma, Barga (LU), Italy for the development of the first plasma-derived factor V product for patients with factor V deficiency and of plasminogen plasma-derived eye drops for patients affected with plasminogen deficiency.
- Clinical leadership in developing and conducting a clinical trial in collaboration with Ablynx, Ghent, Belgium, to test the efficacy of a new drug for the treatment of patients with thrombotic thrombocytopenic purpura, an ultra-rare, acute, life-threatening blood clotting disorder. This drug has demonstrated the potential to become an important new component in the standard of care for thrombotic thrombocytopenic purpura (TTP).

ANNEXES: INVITED SPEAKER TO INTERNATIONAL CONGRESSES – LIST OF PUBLICATIONS

I hereby grant permission to handle my personal data in accordance with the Italian Legislative Decree 196/2003

September 1st, 2023

(F.to)